Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report

(1) Background: Intensive insulin therapy using continuous subcutaneous insulin infusion (CSII) with continuous real-time glucose monitoring (rt CGM) is the best option for patients with T1D. The recent introduction of a technology called Advanced Hybrid Closed Loop (AHCL) represents a new era in th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Tekielak, Sebastian Seget, Ewa Rusak, Przemysława Jarosz-Chobot
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	type 1 diabetes mellitus borderline total daily dose of insulin remission advanced hybrid closed loop systems Chemical technology TP1-1185
Acceso en línea:	https://doaj.org/article/fa5b1e3b8d2746118b64fb07ba60670d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa5b1e3b8d2746118b64fb07ba60670d
record_format	dspace
spelling	oai:doaj.org-article:fa5b1e3b8d2746118b64fb07ba60670d2021-11-11T19:10:59ZCan the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report10.3390/s212171951424-8220https://doaj.org/article/fa5b1e3b8d2746118b64fb07ba60670d2021-10-01T00:00:00Zhttps://www.mdpi.com/1424-8220/21/21/7195https://doaj.org/toc/1424-8220(1) Background: Intensive insulin therapy using continuous subcutaneous insulin infusion (CSII) with continuous real-time glucose monitoring (rt CGM) is the best option for patients with T1D. The recent introduction of a technology called Advanced Hybrid Closed Loop (AHCL) represents a new era in the treatment of type 1 diabetes, the next step towards better care, as well as improving the effectiveness and safety of therapy. The aim is to present the case of a T1D patient with a borderline total daily dose of insulin being treated with the Medtronic AHCL system in automatic mode. (2) Materials and Methods: A 9-year-old boy, from October 2020, with type 1 diabetes in remission was connected to the Minimed™ 780G (AHCL) system in accordance with the manufacturer’s recommendations (daily insulin dose > 8 units, age > 7). Records of the patient’s history were collected from visits to The Department of Children’s Diabetology, as well as from the Medtronic CareLink™ software and the DPV SWEET program from October 2020 to April 2021. (3) Results: The patient’s total daily insulin requirement decreased in the first 6 weeks after the AHCL was connected, which may reflect the remission phase (tight glycemic control with a healthy lifestyle). The lowest daily insulin requirement of 5.7 units was also recorded. In a three-month follow-up of the patient treated with AHCL, it was found that for almost 38% of the days the insulin dose was less than 8 IU. (4) Conclusions: The AHCL system allows safe and effective insulin therapy in automatic mode, as well as in patients with a lower daily insulin requirement. The AHCL system should be considered a good therapeutic option for patients from the onset of T1D, as well in the remission phase.Anna TekielakSebastian SegetEwa RusakPrzemysława Jarosz-ChobotMDPI AGarticletype 1 diabetes mellitusborderline total daily dose of insulinremissionadvanced hybrid closed loop systemsChemical technologyTP1-1185ENSensors, Vol 21, Iss 7195, p 7195 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 1 diabetes mellitus borderline total daily dose of insulin remission advanced hybrid closed loop systems Chemical technology TP1-1185
spellingShingle	type 1 diabetes mellitus borderline total daily dose of insulin remission advanced hybrid closed loop systems Chemical technology TP1-1185 Anna Tekielak Sebastian Seget Ewa Rusak Przemysława Jarosz-Chobot Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
description	(1) Background: Intensive insulin therapy using continuous subcutaneous insulin infusion (CSII) with continuous real-time glucose monitoring (rt CGM) is the best option for patients with T1D. The recent introduction of a technology called Advanced Hybrid Closed Loop (AHCL) represents a new era in the treatment of type 1 diabetes, the next step towards better care, as well as improving the effectiveness and safety of therapy. The aim is to present the case of a T1D patient with a borderline total daily dose of insulin being treated with the Medtronic AHCL system in automatic mode. (2) Materials and Methods: A 9-year-old boy, from October 2020, with type 1 diabetes in remission was connected to the Minimed™ 780G (AHCL) system in accordance with the manufacturer’s recommendations (daily insulin dose > 8 units, age > 7). Records of the patient’s history were collected from visits to The Department of Children’s Diabetology, as well as from the Medtronic CareLink™ software and the DPV SWEET program from October 2020 to April 2021. (3) Results: The patient’s total daily insulin requirement decreased in the first 6 weeks after the AHCL was connected, which may reflect the remission phase (tight glycemic control with a healthy lifestyle). The lowest daily insulin requirement of 5.7 units was also recorded. In a three-month follow-up of the patient treated with AHCL, it was found that for almost 38% of the days the insulin dose was less than 8 IU. (4) Conclusions: The AHCL system allows safe and effective insulin therapy in automatic mode, as well as in patients with a lower daily insulin requirement. The AHCL system should be considered a good therapeutic option for patients from the onset of T1D, as well in the remission phase.
format	article
author	Anna Tekielak Sebastian Seget Ewa Rusak Przemysława Jarosz-Chobot
author_facet	Anna Tekielak Sebastian Seget Ewa Rusak Przemysława Jarosz-Chobot
author_sort	Anna Tekielak
title	Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
title_short	Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
title_full	Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
title_fullStr	Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
title_full_unstemmed	Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
title_sort	can the ahcl system be used in t1d patients with borderline tddi? a case report
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fa5b1e3b8d2746118b64fb07ba60670d
work_keys_str_mv	AT annatekielak cantheahclsystembeusedint1dpatientswithborderlinetddiacasereport AT sebastianseget cantheahclsystembeusedint1dpatientswithborderlinetddiacasereport AT ewarusak cantheahclsystembeusedint1dpatientswithborderlinetddiacasereport AT przemysławajaroszchobot cantheahclsystembeusedint1dpatientswithborderlinetddiacasereport
_version_	1718431622234112000

Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report

Ejemplares similares